Masterflex SE (ISIN: DE0005492938) announced preliminary figures for the 2025 financial year, reporting record earnings that align with its forecast. The company achieved consolidated revenue of EUR 102.6 million, a 4.6% increase from EUR 98.1 million in the prior year, and operating EBITDA rose 7.4% to EUR 19.5 million. Operating EBIT increased 9.8% to EUR 14.0 million, while EBIT grew 9.2% to EUR 13.7 million, all within the targeted ranges of EUR 100-105 million revenue and EUR 12-15 million EBIT.
The US subgroup and medical technology segment were key growth drivers, with medical technology's share of revenue rising from 18% to 21%. Demand in industrial sectors and trading declined only moderately amid economic headwinds, particularly in Germany. The order backlog remained stable at EUR 19.8 million.
Masterflex strengthened its financial position, with the equity ratio improving to 73.3% from 67.7% and net debt falling to EUR 2.7 million from EUR 9.0 million. The debt ratio (net debt/EBITDA) improved to 0.1 from 0.5. CEO Dr. Andreas Bastin noted, 'We met our forecasts, achieved solid revenue growth, and increased profitability thanks to continuous efficiency improvements.'
The preliminary figures are subject to auditor confirmation and Supervisory Board approval. The 2025 consolidated financial statements and 2026 forecast will be published on March 31, 2026. For more details, see the original release on NewMediaWire.
